SGLT2 inhibitors in people with and without T2DM

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study

(2020) Kåre I. Birkeland et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

(2020) Faiez Zannad et al.   LANCET

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

(2020) Milton Packer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

(2020) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE